PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations
Status:
Completed
Trial end date:
2017-11-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, open label, 4-period, 6-sequence, partial cross-over,
single-dose study to evaluate the PK of age-appropriate tofacitinib MR formulations (release
rates: MR-Slow, MR-Moderate, and MR-Fast) compared to tofacitinib IR solution under fasting
conditions. The effect of food on the PK of MR-Slow and MR-Fast will also be assessed.